Samad, A H <br/><br/>
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.  [electronic resource] 

 -  Diabetes care  Apr 1988 
 - 337-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0149-5992 
<br/><br/><label>Standard No.: </label>10.2337/diacare.11.4.337  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>1-Deoxynojirimycin--analogs & derivatives<br/>3-Hydroxybutyric Acid<br/>Alanine--blood<br/>Blood Glucose--metabolism<br/>Clinical Trials as Topic<br/>Diabetes Mellitus, Type 2--blood<br/>Eating<br/>Fatty Acids, Nonesterified--blood<br/>Female<br/>Glucosamine--analogs & derivatives<br/>Glycerol--blood<br/>Glycoside Hydrolase Inhibitors<br/>Humans<br/>Hydroxybutyrates--blood<br/>Hypoglycemic Agents--therapeutic use<br/>Imino Pyranoses<br/>Insulin--blood<br/>Lactates--blood<br/>Male<br/>Middle Aged<br/>Pyruvates--blood